^
Association details:
| Biomarker: | PRSS1 overexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
PRSS contributes to cetuximab resistance in colorectal cancer
Published date:
01/01/2020
Excerpt:
...we divided the patients receiving cetuximab monotherapy into two groups: high and low PRSS1 expression groups. Kaplan-Meier curves for these patients consistently demonstrated much worse overall survival (OS) for the patients with high PRSS1 than that for the patients with low PRSS1 median survival, 83 days versus 206 days, respectively; P = 0.009; Fig. 6D), indicating that a high PRSS1 level was clearly related to a poor cetuximab response in mCRC.
DOI:
10.1126/sciadv.aax5576